Want to see RNXT full AI Analyst Report?
RNXT Stock Chart & Stats
$1.00
-$0.05(-3.65%)
At close: 4:00 PM EST
$1.00
-$0.05(-3.65%)
Day’s Range― - ―
52-Week Range$0.70 - $1.45
Previous CloseN/A
Volume39.72K
Average Volume (3M)288.82K
Market Cap
$38.98M
Enterprise Value$26.24
Total Cash (Recent Filing)$12.36M
Total Debt (Recent Filing)$186.00K
Price to Earnings (P/E)―
Beta0.74
Next Earnings
Aug 13, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.34
Shares Outstanding45,052,708
10 Day Avg. Volume236,040
30 Day Avg. Volume288,821
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)5.47
Price to Sales (P/S)26.43
P/FCF Ratio-2.70
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.00Price Target Upside600.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.3
Revenue Forecast (FY)$3.21M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsRenovoRx’s very high gross margins (85.1% in Q1; ~79% TTM) indicate attractive unit economics for the RenovoCath procedure. Durable margin strength supports scalable profitability as procedures ramp, gives pricing flexibility, and improves the chance of operating leverage as commercial volumes grow.
Commercial Footprint ExpansionRapid growth in active centers (16 from 5 at start of 2025) and a 48-center pipeline show durable commercial adoption. Physician advocacy and repeat orders imply stickiness, which should sustain procedure volume growth, lower per-procedure fixed costs, and strengthen market position versus competitors over months.
Phase III Near CompletionNear-completion of the pivotal TIGeR-PaC trial (106/114 randomized) is a structural catalyst: final data in mid-to-late 2027 could validate clinical benefit, enable broader reimbursement and site conversion, and materially de-risk long-term commercial adoption and addressability for pancreatic cancer treatment.
Bears Say
Persistent Cash BurnRNXT runs material negative operating and free cash flow (~-$11.3M and -$11.2M TTM), which creates ongoing funding dependence and dilution risk. Persistently large burn relative to current revenue constrains discretionary investment, forcing management to prioritize financing over longer-term scaling initiatives.
Low Absolute Revenue & ChunkinessDespite strong growth rates, absolute revenue remains modest (Q1 $563K). Revenue concentration and quarter-to-quarter 'chunkiness' impair predictability, make it harder to cover fixed SG&A and R&D, and increase execution risk: sustained conversion of pipeline centers is required to realize revenue targets and operational breakeven.
Listing & Runway RiskManagement reports cash runway into H2 2027 and Nasdaq has extended a compliance period, leaving listing status and funding as structural overhangs. If commercial ramp slips, the company may need capital before clinical readouts, risking dilution or adverse financing terms and distracting management from execution.
RenovoRx News
RNXT FAQ
What was RenovoRx’s price range in the past 12 months?
RenovoRx lowest stock price was $0.70 and its highest was $1.45 in the past 12 months.
What is RenovoRx’s market cap?
RenovoRx’s market cap is $38.98M.
When is RenovoRx’s upcoming earnings report date?
RenovoRx’s upcoming earnings report date is Aug 13, 2026 which is in 25 days.
How were RenovoRx’s earnings last quarter?
RenovoRx released its earnings results on May 14, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.08 by -$0.01.
Is RenovoRx overvalued?
According to Wall Street analysts RenovoRx’s price is currently Undervalued.
Does RenovoRx pay dividends?
RenovoRx does not currently pay dividends.
What is RenovoRx’s EPS estimate?
RenovoRx’s EPS estimate is -0.07.
How many shares outstanding does RenovoRx have?
RenovoRx has 45,052,708 shares outstanding.
What happened to RenovoRx’s price movement after its last earnings report?
RenovoRx reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.08. Following the earnings report the stock price went down -4.094%.
Which hedge fund is a major shareholder of RenovoRx?
Currently, no hedge funds are holding shares in RNXT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
RenovoRx Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$7.00 (600.00% Upside)
$7.00 (600.00% Upside)
Insider Transactions
Bought Shares
Worth $19.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 6.1%
Last 30 Days ▼ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-26.27%
12-Months-Change
Fundamentals
Return on Equity
-138.61%
Trailing 12-Months
Asset Growth
-12.80%
Trailing 12-Months
Company Description
RenovoRx
RenovoRx, Inc. is a clinical-stage biopharmaceutical firm dedicated to developing therapies for solid tumor malignancies. The company's primary investigational therapy, RenovoGem, is an innovative drug and device combination. It integrates intra-arterial gemcitabine with the RenovoCath system, currently progressing through pivotal Phase III clinical trials for the treatment of locally advanced pancreatic cancer. Established in 2009, RenovoRx, Inc. maintains its headquarters in Los Altos, California.
RNXT Stock 12 Month Forecast
Average Price Target
$7.00
▲(600.00% Upside)
Technical Analysis
Ovid Therapeutics
―
Grace Therapeutics
―
Jasper Therapeutics
―
Neurosense Therapeutics Ltd.
―
PepGen Inc.
―
Ownership Overview
3.53% Insiders
3.91% Mutual Funds
0.03% Other Institutional Investors
89.39% Public Companies and
Individual Investors